# US 2012/0251590 A1 · Controlled release formulations of opioid and nonopioid analgesics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251590 A1
- Document ID: US20120251590A1
- Status: Published application
- Kind: A1
- Application number: 13/436,727
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2003-09-26
- Inventors: Evangeline Cruz; Atul D. Ayer; Brenda J. Pollock; Carmelita Garcia; Sherry Li; Alfredo M. Wong; Lawrence G. Hamel; Cheri Enders Klein; Yihong Qiu; Ye Huang
- Web page: https://patentgrep.com/patent/US20120251590A1

## CPC

- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic.

## Claims

### Claim 1

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
a) an immediate release component;
b) a sustained release component,
wherein said immediate release component and said sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic, wherein said amount of nonopioid analgesic is between about 20 and about 100 times said amount of opioid analgesic by weight, and said sustained release component provides sustained release of each of said opioid analgesic and said nonopioid analgesic at rates proportional to each other in said dosage form.

### Claim 2 (depends on 1)

The sustained release dosage form of claim 1, wherein said nonopioid analgesic has a solubility of less than about 10 mg/mL at 25° C.

### Claim 3 (depends on 1)

The sustained release dosage form of claim 1, wherein said amount of nonopioid analgesic is between about 20 and about 40 times said amount of opioid analgesic by weight.

### Claim 4 (depends on 3)

The sustained release dosage form of claim 3, wherein said amount of nonopioid analgesic is between about 27 and about 34 times said amount of opioid analgesic by weight.

### Claim 5 (depends on 1)

The sustained release dosage form of claim 1, wherein the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone bitartrate.

### Claim 6 (depends on 5)

The sustained release dosage form of claim 5, wherein the sustained release component contains a loading of acetaminophen of at least 60% by weight.

### Claim 7 (depends on 6)

The sustained release dosage form of claim 6, wherein the sustained release component contains a loading of acetaminophen of between about 75% and about 95% by weight.

### Claim 8 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a plasma profile characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg after a single dose.

### Claim 9 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a minimum Cmax for hydrocodone of about 0.4 ng/mL/mg to a maximum Cmax for hydrocodone of about 1.9 ng/mL/mg and a minimum Cmax for acetaminophen of about 2.0 ng/mL/mg and maximum Cmax for acetaminophen of about 10.4 ng/mL/mg after a single dose.

### Claim 10 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for hydrocodone of about 0.8±0.2 ng/mL/mg and a Cmax for acetaminophen of about 4.1±1.1 ng/mL/mg after a single dose.

### Claim 11 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Tmax for hydrocodone of about 1.9±2.1 to about 6.7±3.8 hours after a single dose.

### Claim 12 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Tmax for hydrocodone of about 6.7±3.8 hours after a single dose.

### Claim 13 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Tmax for hydrocodone of about 4.3±3.4 hours after a single dose.

### Claim 14 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Tmax for acetaminophen of about 1.1±1.1 to about 2.8±2.7 hours after a single dose.

### Claim 15 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Tmax for acetaminophen of about 1.1±1.1 hours after a single dose.

### Claim 16 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.

### Claim 17 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a minimum AUC for hydrocodone of about 7.0 ng*hr/mL/mg to a maximum AUC for hydrocodone of about 26.2 ng*hr/mL/mg and a minimum AUC for acetaminophen of about 18.4 ng*hr/mL/mg and maximum AUC for acetaminophen of 79.9 ng*hr/mL/mg after a single dose.

### Claim 18 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces an AUC for hydrocodone of about 15.0±3.7 ng*hr/mL/mg and an AUC for acetaminophen of 41.1±12.4 ng*hr/mL/mg after a single dose.

### Claim 19 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg, and wherein the dosage form produces an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.

### Claim 20 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for hydrocodone of between about 19.4 and 42.8 ng/ml after a single dose of 30 mg hydrocodone.

### Claim 21 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a minimum Cmax for hydrocodone of about 12.7 ng/ml and the maximum Cmax for hydrocodone of about 56.9 ng/mL after a single dose of 30 mg hydrocodone.

### Claim 22 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for hydrocodone of between about 25.3±5.7 ng/ml after a single dose of 30 mg hydrocodone.

### Claim 23 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for acetaminophen of between about 3.0 and about 7.9 μg/ml after a single dose of 1000 mg acetaminophen.

### Claim 24 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a minimum Cmax for acetaminophen of about 2.0 μg/ml and the maximum Cmax of about 10.4 μg/ml after a single dose of 1000 mg acetaminophen.

### Claim 25 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for acetaminophen of between about 4.1±1.1 μg/ml after a single dose of 1000 mg acetaminophen.

### Claim 26 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for hydrocodone exhibits an area under the concentration time curve between about 275 and about 562 ng*hr/ml after a single dose of 30 mg hydrocodone bitartrate.

### Claim 27 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for hydrocodone exhibits a minimum area under the concentration time curve of about 228 ng*hr/ml and a maximum area under the concentration time curve of about 754 ng*hr/ml after a single dose of 30 mg hydrocodone bitartrate.

### Claim 28 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for hydrocodone exhibits an area under the concentration time curve of about 449±113 ng*hr/ml after a single dose of 30 mg hydrocodone bitartrate.

### Claim 29 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for acetaminophen exhibits an area under the concentration time curve between about 28.7 and about 57.1 μg*hr/ml after a single dose of 1000 mg acetaminophen.

### Claim 30 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for acetaminophen exhibits a minimum area under the concentration time curve of about 22.5 μg*hr/ml and a maximum area under the concentration time curve of about 72.2 μg*hr/ml after a single dose of 1000 mg acetaminophen.

### Claim 31 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile for acetaminophen exhibits an area under the concentration time curve of about 41.1±12.4 μg*hr/ml after a single dose of 1000 mg acetaminophen.

### Claim 32 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the dosage form produces a Cmax for hydromorphone of between about 0.12 and about 0.35 ng/ml after a single dose of 30 mg hydrocodone to a non-poor CYP2D6 metabolizer human patient.

### Claim 33 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration for hydrocodone at 12 hours (C12) is between about 11.0 and about 27.4 ng/ml after a single dose of 30 mg hydrocodone bitartrate in a human patient.

### Claim 34 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration for acetaminophen at 12 hours (C12) is between about 0.7 and 2.5 μg/ml after a single dose of 1000 mg acetaminophen in a human patient.

### Claim 35 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile exhibits a width at half height value for hydrocodone of between about 6.4 and about 19.6 hours.

### Claim 36 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile exhibits a width at half height value for acetaminophen of between about 0.8 and about 12.3 hours.

### Claim 37 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile exhibits a weight ratio of acetaminophen to hydrocodone between about 114.2 and 284 at one hour after oral administration of a single dose containing 1000 mg acetaminophen and 30 mg hydrocodone to a human patient.

### Claim 38 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile exhibits a weight ratio of acetaminophen to hydrocodone between about 70.8 and 165.8 at six hours after oral administration of a single dose containing 1000 mg acetaminophen and 30 mg hydrocodone to a human patient.

### Claim 39 (depends on 5)

The sustained release dosage form of claim 5, wherein when administered to the human patient, the plasma concentration profile exhibits a weight ratio of acetaminophen to hydrocodone between about 36.4 and 135.1 at 12 hours after oral administration of a single dose containing 1000 mg acetaminophen and 30 mg hydrocodone to a human patient.

### Claim 40 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for hydrocodone characterized by a first peak concentration (Cmax1) occurring within about 1 to 2 hours after oral administration and a second peak concentration (Cmax2), occurring from about 5 to about 9 hours after oral administration to the human patient.

### Claim 41 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for acetaminophen characterized by a first peak concentration (Cmax1) occurring within about 1 hour after oral administration and a second peak concentration (Cmax2), occurring from about 4 to about 8 hours after oral administration to the human patient.

### Claim 42 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for hydrocodone characterized by a first peak concentration occurring at a time Tmax1 occurring from about 0.4 to about 2.5 hours after oral administration and a second peak concentration occurring at a time Tmax2 occurring from about 2.9 to about 11.4 hours after oral administration to the human patient.

### Claim 43 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for hydrocodone characterized by a first peak concentration occurring at a time Tmax1 occurring at about 1.6±0.9 hours after oral administration and a second peak concentration occurring at a time Tmax2 occurring at about 9.0±2.4 hours after oral administration to the human patient.

### Claim 44 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for acetaminophen characterized by a first peak concentration occurring at a time Tmax1 occurring within about 0.5 to about 1.8 hours after oral administration and a second peak concentration occurring at a time Tmax2 occurring from about 1.7 to about 11.9 hours after oral administration to the human patient.

### Claim 45 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for acetaminophen characterized by a first peak concentration occurring at a time Tmax1 occurring within about 0.7±0.2 hours after oral administration and a second peak concentration occurring at a time Tmax2 occurring from about 7.7±4.2 hours after oral administration to the human patient.

### Claim 46 (depends on 5)

The sustained release dosage form of claim 5, wherein the dosage form produces a plasma concentration profile for hydrocodone further characterized by a minimum concentration (Cmin) between Cmax1 and Cmax2 after oral administration to the human patient.

### Claim 47 (depends on 46)

The sustained release dosage form of claim 46, wherein the Cmax1 for hydrocodone is from about 15.8 ng/mL to about 35.4 ng/mL.

### Claim 48 (depends on 46)

The sustained release dosage form of claim 46, wherein the minimum Cmax1 for hydrocodone is about 5.4 ng/mL and the maximum Cmax1 is about 41.7 ng/mL.

### Claim 49 (depends on 46)

The sustained release dosage form of claim 46, wherein the Cmax2 for hydrocodone is from about 16.2 ng/mL to about 40.5 ng/mL.

### Claim 50 (depends on 46)

The sustained release dosage form of claim 46, wherein the minimum Cmax2 for hydrocodone is about 12.7 ng/mL and the maximum Cmax2 is about 56.9 ng/mL.

### Claim 51 (depends on 46)

The sustained release dosage form of claim 46, wherein the Cmin for hydrocodone is from about 10.1 ng/mL to about 23.5 ng/mL.

### Claim 52 (depends on 46)

The sustained release dosage form of claim 46, wherein the minimum Cmin for hydrocodone is about 5.2 ng/mL and the maximum Cmin is about 30.9 ng/mL.

### Claim 53 (depends on 46)

The sustained release dosage form of claim 46, wherein the dosage form produces a plasma concentration profile for acetaminophen further characterized by a minimum concentration (Cmin) between Cmax1 and Cmax2 after oral administration to the human patient.

### Claim 54 (depends on 53)

The sustained release dosage form of claim 53, wherein the Cmax1 for acetaminophen is from about 2.9 μg/mL to about 7.9 μg/mL.

### Claim 55 (depends on 53)

The sustained release dosage form of claim 53, wherein the minimum Cmax1 for acetaminophen is about 1.6 μg/mL and the maximum Cmax1 is about 10.4 μg/mL.

### Claim 56 (depends on 53)

The sustained release dosage form of claim 53, wherein the Cmax2 for acetaminophen is from about 1.5 μg/mL to about 5.6 μg/mL.

### Claim 57 (depends on 53)

The sustained release dosage form of claim 53, wherein the minimum Cmax2 for acetaminophen is about 1.0 μg/mL and the maximum Cmax2 is about 8.8 μg/mL.

### Claim 58 (depends on 53)

The sustained release dosage form of claim 53, wherein the Cmin for acetaminophen is from about 1.2 μg/mL to about 3.8 μg/mL.

### Claim 59 (depends on 53)

The sustained release dosage form of claim 53, wherein the minimum Cmin for acetaminophen is about 0.7 μg/mL and the maximum Cmin is about 4.5 μg/mL.

### Claim 60 (depends on 1)

The sustained release dosage form of claim 1, wherein the sustained release component comprises:
(1) a semipermeable wall defining a cavity and including an exit orifice formed or formable therein;
(2) a drug layer comprising a therapeutically effective amount of an opioid analgesic and a nonopioid analgesic contained within the cavity and located adjacent to the exit orifice;
(3) a push displacement layer contained within the cavity and located distal from the exit orifice;
(4) a flow-promoting layer between the inner surface of the semipermeable wall and at least the external surface of the drug layer that is opposite the wall;
wherein the dosage form provides an in vitro rate of release of the opioid analgesic and the nonopioid analgesic for up to about 12 hours after being contacted with water in the environment of use.

### Claim 61 (depends on 60)

The sustained release dosage form of claim 60, wherein the drug layer contains a loading of the nonopioid analgesic of at least 60% by weight.

### Claim 62 (depends on 61)

The sustained release dosage form of claim 61, wherein the drug layer contains a loading of the nonopioid analgesic of between about 75% and about 95% by weight.

### Claim 63 (depends on 62)

The sustained release dosage form of claim 62, wherein the drug layer contains a loading of the nonopioid analgesic of between about 80% and about 85% by weight.

### Claim 64 (depends on 60)

The sustained release dosage form of claim 60, wherein the drug layer contains a loading of the opioid analgesic between about 1% and about 10% by weight.

### Claim 65 (depends on 64)

The sustained release dosage form of claim 64, wherein the drug layer contains a loading of the opioid analgesic between about 2% and about 6% by weight.

### Claim 66 (depends on 60)

The sustained release dosage form of claim 60, wherein the amount of the nonopioid analgesic is between about 27 and about 34 times the amount of the opioid analgesic by weight.

### Claim 67 (depends on 60)

The sustained release dosage form of claim 60, wherein the drug layer is exposed to the environment of use as an erodible composition.

### Claim 68 (depends on 60)

The sustained release dosage form of claim 60, wherein the in vitro rate of release of the opioid analgesic and the nonopioid analgesic is zero order or ascending.

### Claim 69 (depends on 60)

The sustained release dosage form of claim 60, wherein the in vitro rate of release of the opioid analgesic and nonopioid analgesic is maintained for from about 6 hours to about 10 hours.

### Claim 70 (depends on 69)

The sustained release dosage form of claim 69, wherein the in vitro rate of release of the opioid analgesic and nonopioid analgesic is maintained for about 8 hours.

### Claim 71 (depends on 60)

The sustained release dosage form of claim 60, wherein the drug layer further comprises a disintegrant, a surfactant, a binding agent, or a gelling agent, or mixtures thereof.

### Claim 72 (depends on 71)

The sustained release dosage form of claim 71, wherein the drug layer further comprises a nonionic surfactant.

### Claim 73 (depends on 71)

The sustained release dosage form of claim 71, wherein the nonionic surfactant is a poloxamer, or a fatty acid ester of polyoxyethylene, or mixtures thereof.

### Claim 74 (depends on 60)

The sustained release dosage form of claim 60, wherein the opioid analgesic is selected from hydrocodone, hydromorphone, oxymorphone, methadone, morphine, codeine, or oxycodone, or pharmaceutically acceptable salts thereof.

### Claim 75 (depends on 60)

The sustained release dosage form of claim 60, wherein the nonopioid analgesic is acetaminophen.

### Claim 76 (depends on 60)

The sustained release dosage form of claim 60, wherein the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone bitartrate.

### Claim 77 (depends on 1)

The sustained release dosage form of claim 1, wherein the immediate release component comprises a drug coating comprising a therapeutically effective amount of an opioid analgesic and nonopioid analgesic sufficient to provide an analgesic effect in a patient in need thereof.

### Claim 78 (depends on 76)

The sustained release dosage form of claim 76, wherein the immediate release component comprises a drug coating comprising a therapeutically effective amount of an hydrocodone bitartrate and acetaminophen sufficient to provide an analgesic effect in a patient in need thereof.

### Claim 79 (depends on 78)

The sustained release dosage form of claim 78, wherein the drug coating comprises from about 60% to about 96.99% acetaminophen by weight.

### Claim 80 (depends on 79)

The sustained release dosage form of claim 79, wherein the drug coating comprises from about 75% to about 89.5% acetaminophen by weight.

### Claim 81 (depends on 78)

The sustained release dosage form of claim 78, wherein the drug coating comprises from about 0.01% to about 25% hydrocodone bitartrate by weight.

### Claim 82 (depends on 81)

The sustained release dosage form of claim 81, wherein the drug coating comprises from about 0.5% to about 15% hydrocodone bitartrate by weight.

### Claim 83 (depends on 78)

The sustained release dosage form of claim 78, wherein the drug coating comprises from about 1% to about 3% hydrocodone bitartrate by weight.

### Claim 84 (depends on 78)

The sustained release dosage form of claim 78, wherein the dosage form exhibits a release rate in vitro of the opioid analgesic and nonopioid analgesic of from about 19% to about 49% released after 0.75 hour, from about 40% to about 70% released after 3 hours, and at least about 80% released after 6 hours.

### Claim 85 (depends on 78)

The sustained release dosage form of claim 78, wherein the dosage form exhibits a release rate in vitro of the opioid analgesic and nonopioid analgesic of from about 19% to about 49% released after 0.75 hour, from about 35% to about 65% released after 3 hours, and at least about 80% released after 8 hours.

### Claim 86 (depends on 78)

The sustained release dosage form of claim 78, wherein the dosage form exhibits a release rate in vitro of the opioid analgesic and nonopioid analgesic of from about 19% to about 49% released after 0.75 hour, from about 35% to about 65% released after 4 hours, and at least about 80% released after 10 hours.

### Claim 87 (depends on 60)

The sustained release dosage form of claim 60, wherein at least 90% of the nonopioid analgesic and at least 90% of the opioid analgesic are released from the dosage form within 12 hours of being contacted with water in the environment of use.

### Claim 88

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
a) an immediate release component;
b) a sustained release component,
wherein said immediate release component and said sustained release component collectively contain a therapeutically effective amount of hydrocodone and a therapeutically effective amount of acetaminophen, wherein said amount of acetaminophen is between about 20 and about 100 times said amount of hydrocodone by weight, and wherein the dosage form produces a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg after a single dose.

### Claim 89 (depends on 88)

The sustained release dosage form of claim 88, wherein said sustained release component provides sustained release of each of said hydrocodone and said acetaminophen at rates proportional to each other.

### Claim 90

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
a) an immediate release component;
b) a sustained release component,
wherein said immediate release component and said sustained release component collectively contain a therapeutically effective amount of hydrocodone and a therapeutically effective amount of acetaminophen, wherein said amount of acetaminophen is between about 20 and about 100 times said amount of hydrocodone by weight, and wherein the dosage form produces an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.

### Claim 91 (depends on 90)

The sustained release dosage form of claim 90, wherein said sustained release component provides sustained release of each of said hydrocodone and said acetaminophen at rates proportional to each other.

### Claim 92

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
a) an immediate release component;
b) a sustained release component,
wherein said immediate release component and said sustained release component collectively contain a therapeutically effective amount of hydrocodone and a therapeutically effective amount of acetaminophen, wherein said amount of acetaminophen is between about 20 and about 100 times said amount of hydrocodone by weight, wherein the dosage form exhibits a plasma concentration profile for hydrocodone characterized by a first peak concentration (Cmax1) occurring within about 1 to 2 hours after oral administration and a second peak concentration (Cmax2), occurring from about 5 to about 9 hours after oral administration to the human patient.

### Claim 93

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
an immediate release component; and
a sustained release component,
wherein said immediate release component and said sustained release component collectively provide a therapeutically effective amount of a nonopioid analgesic and an opioid analgesic, and wherein said immediate release component and said sustained release component provide a means for providing a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg after a single dose in the plasma of the patient.

### Claim 94

A sustained release dosage form for twice daily oral dosing to a human patient, comprising
an immediate release component; and
a sustained release component,
wherein said immediate release component and said sustained release component collectively provide a therapeutically effective amount of a nonopioid analgesic and an opioid analgesic, and wherein said immediate release component and said sustained release component provide a means for providing an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.

### Claim 95

A method for treating pain in a human patient, comprising orally administering to the human patient on a twice-a-day basis an oral sustained release dosage form comprising:
(1) a semipermeable wall defining a cavity and including an exit orifice formed or formable therein;
(2) a drug layer comprising a therapeutically effective amount of an opioid analgesic and a nonopioid analgesic contained within the cavity and located adjacent to the exit orifice;
(3) a push displacement layer contained within the cavity and located distal from the exit orifice;
(4) a flow-promoting layer between the inner surface of the semipermeable wall and at least the external surface of the drug layer that is opposite the wall;
wherein the dosage form provides an in vitro rate of release of the opioid analgesic and the nonopioid analgesic for up to about 12 hours after being contacted with water in the environment of use.

### Claim 96 (depends on 95)

The method of claim 95, wherein the drug layer contains a loading of the nonopioid analgesic of at least 60% by weight.

### Claim 97 (depends on 96)

The method of claim 96, wherein the drug layer contains a loading of the nonopioid analgesic of between about 75% and about 95% by weight.

### Claim 98 (depends on 97)

The method of claim 97, wherein the drug layer contains a loading of the nonopioid analgesic of between about 80% and about 85% by weight.

### Claim 99 (depends on 95)

The method of claim 95, wherein the drug layer contains a loading of the opioid analgesic between about 1% and about 10% by weight.

### Claim 100 (depends on 96)

The method of claim 96, wherein the drug layer contains a loading of the opioid analgesic between about 2% and about 6% by weight.

### Claim 101 (depends on 95)

The method of claim 95, wherein the amount of the nonopioid analgesic is between about 20 and about 100 times the amount of the opioid analgesic by weight.

### Claim 102 (depends on 101)

The method of claim 101, wherein the amount of the nonopioid analgesic is between about 20 and about 40 times the amount of the opioid analgesic by weight.

### Claim 103 (depends on 102)

The method of claim 102, wherein the amount of the nonopioid analgesic is between about 27 and about 34 times the amount of the opioid analgesic by weight.

### Claim 104 (depends on 95)

The method of claim 95, wherein the dosage form releases the opioid analgesic and the nonopioid analgesic at proportional rates relative to each other.

### Claim 105 (depends on 95)

The method of claim 95, wherein the drug layer is exposed to the environment of use as an erodible composition.

### Claim 106 (depends on 95)

The method of claim 95, wherein the in vitro rate of release of the opioid analgesic and the nonopioid analgesic is zero order or ascending.

### Claim 107 (depends on 95)

The method of claim 95, wherein the in vitro rate of release of the opioid analgesic and nonopioid analgesic is maintained for from about 6 hours to about 10 hours.

### Claim 108 (depends on 95)

The method of claim 95, wherein the in vitro rate of release of the opioid analgesic and nonopioid analgesic is maintained for about 8 hours.

### Claim 109 (depends on 95)

The method of claim 95, wherein said opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof.

### Claim 110 (depends on 95)

The method of claim 95, wherein said nonopioid analgesic is acetaminophen.

### Claim 111 (depends on 95)

The method of claim 95, further comprising a drug coating comprising an effective amount of an immediate release analgesic composition located on the outside surface of the at least partially semipermeable wall.

### Claim 112 (depends on 111)

The method of claim 111, wherein the dosage form produces a plasma profile characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 μg/mL/mg and 7.9 μg/mL/mg in the human patient after a single dose.

### Claim 113 (depends on 111)

The method of claim 111, wherein the dosage form produces a plasma profile characterized by an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.

### Claim 114

A method for providing an effective amount of an analgesic composition for treating pain in a human patient in need thereof, comprising orally admitting into a patient in need thereof a high load dosage form comprising an effective dose of an opioid analgesic agent and a nonopioid analgesic agent contained in a drug layer and an osmotic push composition, wherein said drug layer and push compositions are surrounded by an at least partially semipermeable wall permeable to the passage of water and impermeable to the passage of said analgesic agents, and an exit means in the wall for delivering the analgesic composition from the dosage form, wherein in operation, water enters through the at least partially semipermeable wall into the dosage form causing the osmotic push composition to expand and push the drug layer through the exit means, wherein the drug layer is exposed to the environment of use as an erodible composition, and wherein the nonopioid analgesic and the opioid analgesic are delivered at a controlled rate over a sustained period of time up to about 12 hours providing a therapeutically effective dose to the patient in need thereof.

### Claim 115 (depends on 114)

The method of claim 114, wherein the dosage form is administered on a twice daily basis for the treatment of pain.

### Claim 116 (depends on 114)

The method of claim 114, wherein the analgesic composition further comprises a drug coating providing an immediate delivery of an effective dose of an opioid analgesic agent and a nonopioid analgesic agent to a patient in need thereof.

### Claim 117

A method for providing an effective concentration of an opioid analgesic and nonopioid analgesic in the plasma of a human patient for the treatment of pain, comprising orally admitting into a patient in need thereof a high load dosage form comprising an effective dose of an opioid analgesic agent and a nonopioid analgesic agent contained in a drug layer, an osmotic displacement composition, wherein said drug layer and displacement compositions are surrounded by an at least partially semipermeable wall permeable to the passage of water and impermeable to the passage of said analgesic agents, and an exit means in the wall for delivering the analgesic composition from the dosage form, wherein in operation, water enters through the at least partially semipermeable wall into the dosage form causing the osmotic displacement composition to expand and push the drug layer through the exit means, wherein the drug layer is exposed to the environment of use as an erodible composition, and wherein the nonopioid analgesic and the opioid analgesic are delivered at a proportional rate over a sustained period of time up to about 12 hours.

### Claim 118 (depends on 117)

The method of claim 117, wherein the analgesic composition further comprises a drug coating providing an immediate delivery of an effective dose of an opioid analgesic agent and a nonopioid analgesic agent to a patient in need thereof.

### Claim 119 (depends on 118)

The method of claim 118, wherein said opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and wherein said nonopioid analgesic is acetaminophen.

### Claim 120 (depends on 119)

The method of claim 119, wherein the dosage form produces a plasma profile characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg in the human patient after a single dose.

### Claim 121 (depends on 119)

The method of claim 119, wherein the dosage form produces a plasma profile characterized by an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg after a single dose.
